BK Irons, RS Greene, TA Mazzolini, KL … - Pharmacotherapy, 2006 - PPI Brian K. Irons, Pharm.D., Ronald Shane Greene, Pharm.D., Timothy A. Mazzolini,
Pharm.D., Krystal L. Edwards, Pharm.D., and Rebecca B. Sleeper, Pharm.D. ...
Clinical data suggest that thiazolidinediones—specifically, rosiglitazone ... Cited by 27 - Related articles - BL Direct - All 3 versions
ST de Dios, RC OBrien, PJ Little - Current Diabetes Reviews, 2006 - ingentaconnect.com Stephanie T. de Dios1, Richard C. O'Brien2 and Peter J. Little3,* ...
1Department of Physiology and Pharmacology, School of Medical Sciences, Faculty
of Medicine, The University of New South Wales, Sydney, New South Wales, ... Cited by 3 - Related articles - BL Direct - All 2 versions
REL PharmD, DK PharmD - Progress in Cardiovascular Nursing - interscience.wiley.com The incidence of obesity and type 2 diabetes mellitus (DM2) in the United States
has been increasing dramatically over the past 15 years, and is now at epidemic
proportions. DM2 is the clinical manifestation of a long-term metabolic ... Related articles - BL Direct - All 3 versions
F Pharmacotherapy - medscape.com Clinical data suggest that thiazolidinediones—specifically, rosiglitazone and
pioglitazone—may improve cardiovascular risk factors through multiple
mechanisms. Low insulin sensitivity has been described as an independent ... Related articles
H Failure, T Use - medscape.com Clinical data suggest that thiazolidinediones-specifically, rosiglitazone and
pioglitazone-may improve cardiovascular risk factors through multiple
mechanisms. Low insulin sensitivity has been described as an independent ... Related articles - All 4 versions
P FISIOTERAPIA - unimep.br Page 1. UNIVERSIDADE METODISTA DE PIRACICABA FACULDADE DE CIÊNCIAS DA SAÚDE
PROGRAMA DE PÓS-GRADUAÇÃO EM FISIOTERAPIA “UTILIZAÇÃO ... Related articles - All 2 versions